Press Coverage

From Concept to Clearance: Why It's So Expensive to Develop New CV Drugs

Article about a JAMA study showing new cardiovascular drugs are developed at a cost more than 100-fold higher than the average refers to a paper co-authored by ISMP's senior scientist, Thomas Moore, that examined expenses associated with clinical trials and the factors that contribute to those costs.

For the full text, visit Cardiovascular Business online.


More News

ECRI Institute and the Institute for Safe Medication Practices (ISMP) announce the successful completion of their plans to join forces. Effective today, ISMP is an ECRI Institute affiliate. By joining together, the two patient safety leaders have created one of the largest healthcare quality and